The consumer health business model leaves little room for US marketers to maneuver in light of the Trump administration's Chinese import tariffs, and OTC industry representatives are dismayed their products haven't been shielded as the tariff plan moves forward.
Active ingredients and excipients used in OTC drugs are among the items subject to an added 10% tariff when imported from China to the US